^
Association details:
| Biomarker: | HER-2 underexpression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Aidixi (disitamab vedotin) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study
Published date:
12/15/2023
Excerpt:
Compared with RC48 monotherapy, ICIs plus RC48 demonstrated superior third-line and beyond therapeutic efficacy for HER2-positive or HER2-low advanced and metastatic gastric cancer patients with manageable safety.
Secondary therapy:
Immune Checkpoint Inhibitors
DOI:
10.1186/s12885-023-11735-z.
